RUBY-1: A randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome - Steg, PG; Mehta, SR; Jukema, JW (Eur Heart J, 2011)
et al.